Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Hat Trick For Roche's Gazyva In Lymphoma

Executive Summary

Roche's Gazyva/Gazyvaro missed its primary endpoint in a Phase III study in first-line diffuse large B-cell lymphoma, failing to score a treble in lymphoma indications for the product, which the company is relying on to replace revenues from the increasingly biosimilared rituximab. The failure has also brought to investors' minds the larger uncertainty over Perjeta's future in breast cancer in the APHINITY study.

You may also be interested in...

Gazyva’s GALLIUM Could Be ‘Practice-Changing’ For Follicular Lymphoma

Genentech’s next-generation anti-CD20 antibody Gazyva bested the Roche subsidiary’s original CD20-targeting therapy Rituxan in first-line follicular lymphoma – a result in the Phase III GALLIUM study that one oncologist viewed as “practice-changing.”

ASH 2016 Preview: Don't Miss These 10 Data Presentations

A CAR-T late breaker from Kite Pharma and sickle cell disease updates from recently acquired Oklahoma biotech, Selxys, lead Scrip's handpicked top 10 data presentations you shouldn't miss at this year's American Society for Hematology annual meeting, held in San Diego, Dec. 2-6.

Spate Of Late-Stage DLBCL Trial Failures Leaves Spoils Waiting

A run of bad luck for developers of potential treatments for diffuse large B-cell lymphoma – Roche, Celgene and Novartis – has withered the late-stage pipeline for an indication that has long been in need of new therapies. Scrip and Datamonitor Healthcare take a look at what's next for the disease.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts